From Medscape Dermatology

Coverage from the

American Academy of Dermatology (AAD) 2022 Annual Meeting

March 25 - 29, 2022; Hybrid/Boston, Massachusetts

March 25 - 29, 2022 Hybrid/Boston, Massachusetts

AAD 2022 JAK Inhibitors Improve Vitiligo, Trials Show Separate clinical trials of ruxolitinib and ritlecitinib showed both therapies resulted in significant repigmentation in patients with vitiligo.
Medscape Medical News, April 8, 2022
AAD 2022 For Pemphigus, Rituximab Is First Line, Expert Says Lower healthcare costs and efficacy put rituximab ahead of traditional treatments, such as corticosteroids, doxycycline, and immunomodulators, for the autoimmune blistering disease, an expert said.
Medscape Medical News, March 31, 2022
AAD 2022 Cellulitis Care Costly From Misdiagnosis, Needless Hospitalizations The skin infection cellulitis is a major and growing consumer of healthcare resources, but there are large potential cost savings for each step in care management, including involving dermatologists.
Medscape Medical News, March 29, 2022

Conference News

AAD 2022 Synthetic, Botanical Agents Emerging as Promising for Melasma
Medscape Medical News, May 17, 2022
AAD 2022 Dermatology Residency Focuses on Rural Placement of Graduates
Medscape Medical News, May 11, 2022
AAD 2022 PLA Test Brings Nuance to the Diagnosis of Early-Stage Melanoma
Medscape Medical News, April 12, 2022
AAD 2022 JAK Inhibitors Improve Vitiligo, Trials Show
Medscape Medical News, April 8, 2022
AAD 2022 Apremilast's Effect on CVD Risk Markers Evaluated in Study
Medscape Medical News, April 6, 2022
AAD 2022 For Pemphigus, Rituximab Is First Line, Expert Says
Medscape Medical News, March 31, 2022
AAD 2022 Dupilumab Treats Itch and Clears Lesions in Prurigo Nodularis Patients
Medscape Medical News, March 31, 2022
AAD 2022 COVID Vaccine Skin Reactions No Reason to Forgo Second Dose
Medscape Medical News, March 30, 2022
AAD 2022 COVID-19 Outcomes in AD Patients: Registry Data Reported
Medscape Medical News, March 30, 2022

AAD 2022 Cellulitis Care Costly From Misdiagnosis, Needless Hospitalizations
Medscape Medical News, March 29, 2022
AAD 2022 Clinical Clarity Grows About Toenail Disorder, Experts Report
Medscape Medical News, March 27, 2022
AAD 2022 Novel Isotretinoin Ointment for Congenital Ichthyosis Shows Promise
Medscape Medical News, March 27, 2022
AAD 2022 Sustained Jawline Definition From Hyaluronic Gel, Study Reports
Medscape Medical News, March 27, 2022
AAD 2022 New Trial Data Show Hair Growth in More Alopecia Areata Patients
Medscape Medical News, March 26, 2022
AAD 2022 Study Links COVID-19 to Autoimmune and Vascular Diseases
Medscape Medical News, March 26, 2022
AAD 2022 Topical Options for Treating Melasma Continue to Expand
Medscape Medical News, March 26, 2022
AAD 2022 Platelet-Rich Plasma for Hair Regrowth Requires Art and Science
Medscape Medical News, March 26, 2022

Popular News from AAD VMX 2021

Reports Further Characterize COVID Vaccine Skin Reactions Delayed large local skin reactions after receiving one of the mRNA COVID-19 vaccines were the most commonly reported to the AAD–International League of Dermatological Societies registry.
Medscape Medical News, May 12, 2021
Experts Say Teledermatology's Post-Pandemic Role Is Unclear There are many unknowns, not least of which is future reimbursement from the Centers for Medicare & Medicaid Services and other third-party payers.
Medscape Medical News, Apr 27, 2021
Debate: Should Biologics Be Used for Milder Cases of Psoriasis? The remarkable efficacy of biologics for moderate-to-severe psoriasis has led some to ask if biologics should be used for milder cases.
Medscape Medical News, Apr 25, 2021

Medscape Dermatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Atopic Dermatitis Highlights From AAD 2022
Lindsay C. Strowd, MD

Previous Coverage

Related Resources